J Med Assoc Thai 2011; 94 (3):46

Views: 1,390 | Downloads: 166 | Responses: 0

PDF XML Respond to this article Print Alert & updates Request permissions Email to a friend


Serum AFP and AFP-L3 in Clinically Distinguished Hepatocellular Carcinoma from Patients with Liver Masses
Subwongcharoen S Mail, Leelawat K , Treepongkaruna S , Narong S

Objective: To determine the ability of alpha fetoprotein (AFP) and AFP-L3% serum level in discriminating hepatocellular
carcinoma (HCC) from other types of liver mass.

Material and Method:
This study was performed according to a prospective-specimen-collection, retrospective-blindedevaluation
(PRoBE) design. A total of 109 HCC patients and 51 patients with other types of liver mass were consecutively
selected. The levels of AFP and AFP-L3% in their sera were measured.

Results:
AFP levels in serum significantly elevated while AFP-L3% levels significantly decreased in HCC patients (AFP: p <
0.001, AFP-L3%: p < 0.001). The area under the curve (AUC) of a receiver operating characteristic (ROC) curve analysis
for the diagnosis of HCC of AFP and AFP-L3% was 0.71 and 0.67, respectively. In addition, the serum level of AFP-L3% was
significantly different between the small (mass occupying lesser than 50% of liver volume) and large (mass occupying more
than 50% of liver volume) HCC (p = 0.040).

Conclusion:
The diagnostic accuracy of serum AFP and AFP-L3% could provide them as candidate biomarkers to discriminate
patients with HCC from patients with other types of liver mass. Serum AFP-L3% as a prognostic factor for HCC should be
further evaluated in more details.

Keywords: AFP, AFP-L3%, Hepatocellular carcinoma

Download: PDF